This Article Full Text Full Text (PDF) All Versions of this Article: 109/13/1590    most recent 01.CIR.0000125521.40985.28v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, M. L. Articles by Koch, W. J. Search for Related Content PubMed PubMed Citation Articles by Williams, M. L. Articles by Koch, W. J. Related Collections Contractile function Congestive Other Treatment Chronic ischemic heart disease

(Circulation. 2004;109:1590-1593.)
© 2004 American Heart Association, Inc.

Brief Rapid Communication

Targeted ß-Adrenergic Receptor Kinase (ßARK1) Inhibition by Gene Transfer in Failing Human Hearts

Matthew L. Williams, MD^*; Jonathan A. Hata, MD^*; Jacob Schroder, MD; Edward Rampersaud, MD; Jason Petrofski, MD; Andre Jakoi, BS; Carmelo A. Milano, MD; Walter J. Koch, PhD

From the Department of Surgery, Duke University Medical Center (M.L.W., J.A.H., J.S., E.R., J.P., A.J., C.A.M., W.J.K.), Durham, NC; Department of Surgery, Massachusetts General Hospital (M.L.W.), Boston, Mass; and Center for Translational Medicine (W.J.K.), Thomas Jefferson University, Philadelphia, Pa.

Correspondence to Walter J. Koch, PhD, FAHA, Director, Center for Translational Medicine, Jefferson Medical College, 1025 Walnut St, Room 410, Philadelphia, PA 19107. E-mail walter.koch{at}jefferson.edu

Received December 16, 2003; revision received February 12, 2004; accepted February 18, 2004.

Background— Failing human myocardium is characterized by an attenuated contractile response to ß-adrenergic receptor (ßAR) stimulation due to changes in this signaling cascade, including increased expression and activity of the ß-adrenergic receptor kinase (ßARK1). This leads to desensitization and downregulation of ßARs. Previously, expression of a peptide inhibitor of ßARK1 (ßARKct) has proven beneficial in several animal models of heart failure (HF).

Methods and Results— To test the hypothesis that inhibition of ßARK1 could improve ß-adrenergic signaling and contractile function in failing human myocytes, the ßARKct was expressed via adenovirus-mediated (AdßARKct) gene transfer in ventricular myocytes isolated from hearts explanted from 10 patients with end-stage HF undergoing cardiac transplantation. AdßARKct also contained the marker gene, green fluorescent protein, and successful gene transfer was confirmed via fluorescence and immunoblotting. Compared with uninfected failing myocytes (control), the velocities of both contraction and relaxation in the AdßARKct-treated cells were increased in response to the ß-agonist isoproterenol (contraction: 57.5±6.6% versus 37.0±4.2% shortening per second, P<0.05; relaxation: 43.8±5.5% versus 27.5±3.9% lengthening per second, P<0.05). Fractional shortening was similarly enhanced (12.2±1.2% versus 8.0±0.9%, P<0.05). Finally, adenylyl cyclase activity in response to isoproterenol was also increased in AdßARKct-treated myocytes.

Conclusions— These results demonstrate that as in animal models of HF, expression of the ßARKct can improve contractile function and ß-adrenergic responsiveness in failing human myocytes. Thus, ßARK1 inhibition may represent a therapeutic strategy for human HF.

Key Words: myocytes • heart failure • gene therapy

This article has been cited by other articles:

				L. E. Vinge, P. W. Raake, and W. J. Koch Gene Therapy in Heart Failure Circ. Res., June 20, 2008; 102(12): 1458 - 1470. [Abstract] [Full Text] [PDF]

				C. Perrino, J. N. Schroder, B. Lima, N. Villamizar, J. J. Nienaber, C. A. Milano, and S. V. Naga Prasad Dynamic Regulation of Phosphoinositide 3-Kinase-{gamma} Activity and -Adrenergic Receptor Trafficking in End-Stage Human Heart Failure Circulation, November 27, 2007; 116(22): 2571 - 2579. [Abstract] [Full Text] [PDF]

				T. Tang and H. K. Hammond Cell-Based GATA4 Cardiac Gene Transfer Using Cell-Penetrating Peptide Circ. Res., June 8, 2007; 100(11): 1540 - 1542. [Full Text] [PDF]

				M. A. Nordlie, L. E. Wold, B. Z. Simkhovich, C. Sesti, and R. A. Kloner Molecular Aspects of Ischemic Heart Disease: Ischemia/Reperfusion-Induced Genetic Changes and Potential Applications of Gene and RNA Interference Therapy Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 17 - 30. [Abstract] [PDF]

				C. Nakajima-Takenaka, S. Sakata, S. Kato, Y. Ohga, K.-y. Murata, S. Taniguchi, and M. Takaki Detrimental effects after dobutamine infusion on rat left ventricular function: mechanical work and energetics Exp Physiol, July 1, 2005; 90(4): 635 - 644. [Abstract] [Full Text] [PDF]